27
Views
0
CrossRef citations to date
0
Altmetric
Research Article

IMPACT OF LEUPROLIDE ACETATE DISEASE MANAGEMENT PROGRAM ON PATIENT OUTCOMES

, &
Pages 33-42 | Published online: 06 Oct 2002
 

ABSTRACT

Background: Patient compliance and completion of a recommended course of therapy is strongly associated with improvement in patient outcomes.

Objectives: To implement and evaluate the impact of the Lupron Depot patient education/disease management program.

Methods: This is a prospective follow-up study of 3157 patients receiving Lupron therapy. Patients were evaluated at the beginning of therapy, and then received printed educational materials as well as live educational sessions over the telephone. Patients were instructed to report any encountered/suspected side effects to a 24-hour hotline. Additional telephone interviews were conducted as needed for education and disease management.

Results: A total of 3,153 patients were enrolled in the study, and a total of 1356 telephone-conferences were conducted. Patient compliance with therapy increased from 74% to 98.6%. This program promoted proper utilization of healthcare resources, minimized ER visits and reduced disease complications with an estimated cost savings of $4,020,140. While the frequency of several side effects such as headache, general pain and hot flashes was similar to what was previously reported, the frequency of others was significantly higher e.g., weight changes 14.8% (compared with 3%), joint disorder/pain 76.7% (compared with 7.8–11.7%), depression 35.5% (compared with 10.8%), and night sweats 48.6% (compared with 5.3%). Possible Lupron-induced hypertension that required drug treatment was discovered in 7.04% of the population. Subjective analysis revealed improvement in patient satisfaction with the program.

Conclusion: Patient education and follow-up programs are essential to improve patient outcomes. These programs also add to our understanding of adverse effects of medications.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.